IGF-1 LR3 (Long R3 IGF-1): What It Is, What the Evidence Shows, and Its Legal Status

IGF-1 LR3 is a lab-made, longer-lasting version of IGF-1, a growth-promoting hormone your liver releases when growth hormone tells it to. It was built as a tool for growing cells in labs, and as of October 2026 it isn’t FDA-approved for any use. We found no published human trial of it. ⚠ NEEDS MEDICAL REVIEW That makes it very different from mecasermin (Increlex), the approved IGF-1 drug for a rare growth disorder in children. It’s also different from the “peptides” that nudge your body to make more of its own IGF-1.

If you heard about IGF-1 LR3 from a gym friend, a podcast, or a video promising muscle, here’s the short version. The animal research shows real, potent biology. We found no published study testing it in people. The only place most people can get it is a “research use only” website with no prescription and no medical oversight. The rest of this page walks through what that actually means.

What is IGF-1 LR3?

IGF-1 LR3 (also written IGF1 LR3, IGF 1 LR3, IGF-LR3, Long R3 IGF-1, or LR3-IGF-I) is an analogue of human IGF-1. An analogue is a modified copy. It differs from your body’s own IGF-1 in two ways. One building block (an amino acid) at position 3 is swapped: arginine replaces glutamic acid. That’s the “R3” in the name. It also has an extra 13-amino-acid tail added to the front, which is the “Long” part.

That brings it to 83 amino acids in total. You’ll often see it called the “IGF-1 LR3 peptide,” but at that length it’s technically a small protein. Peptides are usually defined as shorter chains (see what peptides are). That distinction sounds academic, but it matters for its legal status, as the legal section below explains.

IGF-1 LR3 wasn’t designed as a medicine. It was developed and sold as a cell-culture supplement, an ingredient added to the nutrient liquid that labs and drug manufacturers use to grow cells. Repligen, which makes the commercial “LONG R³ IGF-I” product, states on its own FAQ that it “is not approved or permitted for use in any human application.”

What does IGF-1 LR3 do?

IGF-1 LR3 switches on the IGF-1 receptor, the docking point on cells that IGF-1 switches on to signal growth. ⚠ NEEDS MEDICAL REVIEW The difference is in what happens before it gets there. Your blood is full of IGF binding proteins, carrier proteins that hold IGF-1 and limit how much is active at once. ⚠ NEEDS MEDICAL REVIEW In early animal research, those carrier proteins barely grabbed IGF-1 LR3. It bound about 1,000 times more weakly to the main carrier protein, so more of it stayed free to act (Tomas et al., 1993). ⚠ NEEDS MEDICAL REVIEW The same research found it was cleared from the blood faster than IGF-1 (Tomas et al., 1993). ⚠ NEEDS MEDICAL REVIEW

That design produced real effects in animals. In normal rats, IGF-1 LR3 was about 6 times more potent than IGF-1 for growth over 14 days (Tomas et al., 1993). ⚠ NEEDS MEDICAL REVIEW Rats also showed big increases in gut weight (Steeb et al.). ⚠ NEEDS MEDICAL REVIEW Guinea pigs showed similar increases in gut and organ weight (Conlon et al.). ⚠ NEEDS MEDICAL REVIEW So “there’s no evidence it does anything” isn’t accurate. A fairer summary is “real, potent biology in animals, untested in people.”

The animal story is mixed, though, not simply “more muscle.” When the same research group injected it instead of delivering it as a slow, steady infusion, it was “barely equipotent” with ordinary IGF-1 for reversing muscle loss in rats on a steroid drug. ⚠ NEEDS MEDICAL REVIEW In other words, it worked about as well as regular IGF-1, not better. In older pigs, it actually reduced growth and lowered the animals’ own growth hormone and IGF-1 (PubMed 9488001). ⚠ NEEDS MEDICAL REVIEW How much of any of this carries over to people is unknown.

Has IGF-1 LR3 been tested in humans?

We found no published human trial of IGF-1 LR3 of any kind. ⚠ NEEDS MEDICAL REVIEW A 2026 review in Frontiers in Endocrinology sorts the “research compounds” that act on the growth hormone and IGF-1 system into evidence tiers. IGF-1 LR3 is among the compounds it covers, and the review’s lowest tier is “a complete absence of human studies” (Frontiers in Endocrinology, 2026).

What does exist in people is research on native IGF-1, the same molecule your body makes. That’s a different molecule from LR3, but it shows the pathway can do something in humans. In 10 adults with a genetic condition that leaves them short on IGF-1, 8 weeks of lab-made native IGF-1 raised lean mass (PubMed 10999782). ⚠ NEEDS MEDICAL REVIEW In a 4-week study of elderly women, a high dose also raised lean mass. That group reported headaches, lethargy, and joint swelling (JCEM, 1995). ⚠ NEEDS MEDICAL REVIEW In 15 adults with myotonic dystrophy type 1, an inherited muscle-wasting disease, 24 weeks of native IGF-1 paired with its main carrier protein raised lean mass by about 2 kg, but muscle strength and day-to-day function didn’t improve (Heatwole et al., 2011). ⚠ NEEDS MEDICAL REVIEW That trial had no comparison group, and three people had episodes of low blood sugar. ⚠ NEEDS MEDICAL REVIEW

The results in healthy, active people were mixed. In 56 recreational athletes, an IGF-1 combination product taken for 28 days didn’t change lean mass or fat mass (PubMed 26046967). ⚠ NEEDS MEDICAL REVIEW It did raise VO2max, the most oxygen your body can use during hard exercise, by about 7%, while the placebo group didn’t change (Guha et al., 2015). ⚠ NEEDS MEDICAL REVIEW So native IGF-1 may do more for endurance than for muscle size, at least over four weeks. Those trials were small, and none of them tested LR3. They tell you the pathway is real in people, not what IGF-1 LR3 does in people.

IGF-1 LR3 side effects and safety unknowns

There is no human safety data for IGF-1 LR3 itself. ⚠ NEEDS MEDICAL REVIEW The most honest way to answer “how risky is it?” is to look at what the approved IGF-1 drug’s label shows about this class of compound, then be clear about what’s unknown.

The Increlex (mecasermin) label reports hypoglycemia, meaning blood sugar dropping too low, in 42% of trial patients (30 of 71). ⚠ NEEDS MEDICAL REVIEW Its warnings include severe hypoglycemia that can lead to seizures. ⚠ NEEDS MEDICAL REVIEW They also include allergic reactions, up to anaphylaxis (a severe, whole-body allergic reaction). ⚠ NEEDS MEDICAL REVIEW The label also warns about raised pressure inside the skull and enlarged tonsils and adenoids. ⚠ NEEDS MEDICAL REVIEW It warns about malignant neoplasia, meaning cancerous growths, and tells doctors to “monitor all patients… for development of neoplasms.” ⚠ NEEDS MEDICAL REVIEW It isn’t to be used in anyone with active or suspected cancer (Increlex label). ⚠ NEEDS MEDICAL REVIEW Keep in mind who that label describes: children with a rare deficiency, under a specialist’s care.

The cancer question comes up a lot, and the honest answer is “unknown.” The concern is theoretical. IGF-1 is a growth signal, and IGF-1 LR3 was built to slip past the carrier proteins that normally keep that signal in check. ⚠ NEEDS MEDICAL REVIEW No human data shows what LR3 does to cancer risk, in either direction. ⚠ NEEDS MEDICAL REVIEW (For more on IGF-1 signaling and aging research, see our longevity and anti-aging peptides hub.)

There’s also a separate risk that has nothing to do with the molecule: what’s actually in the vial. That’s covered in where IGF-1 LR3 is actually sold below. ⚠ NEEDS MEDICAL REVIEW

IGF-1 LR3 vs. IGF-1 and mecasermin (Increlex)

These three often get mixed up online. They are not the same thing.

Mecasermin is genuinely worth knowing about. It shows that IGF-1 can be a legitimate, FDA-approved medicine. But its approval is narrow. It covers a rare condition in children, and its label says it is “not a substitute to GH for approved GH indications.” That approval doesn’t extend to IGF-1 LR3, to adults, or to muscle building.

IGF-1 LR3 also works differently from sermorelin, tesamorelin, and ipamorelin. Those prompt your body to release more growth hormone, which then raises your own IGF-1. ⚠ NEEDS MEDICAL REVIEW IGF-1 LR3 skips that chain because it’s a modified IGF-1 itself. ⚠ NEEDS MEDICAL REVIEW

IGF-1 LR3 vs. IGF-1 DES

IGF-1 DES is another lab-made variant you’ll see mentioned alongside LR3. It’s a shortened IGF-1 with its first three amino acids removed. Like LR3, it’s designed to escape the carrier proteins in your blood. ⚠ NEEDS MEDICAL REVIEW We found no published human trial of either compound, so there’s no human evidence to say one works better or is safer than the other. ⚠ NEEDS MEDICAL REVIEW

Is IGF-1 LR3 better than HGH?

There’s no way to know, because we found no published human study of IGF-1 LR3 to compare against. ⚠ NEEDS MEDICAL REVIEW Growth hormone (HGH) and IGF-1 LR3 act at different points in the same chain. Growth hormone signals your liver to make IGF-1, and LR3 is a modified IGF-1 itself. ⚠ NEEDS MEDICAL REVIEW The human evidence on growth hormone and muscle lives on our peptides for muscle growth hub.

As for whether IGF-1 LR3 raises testosterone, there’s no human data on LR3 and we know of no established mechanism by which it would. ⚠ NEEDS MEDICAL REVIEW The closest data point is the small myotonic dystrophy trial above, where men’s testosterone rose on native IGF-1 (Heatwole et al., 2011). ⚠ NEEDS MEDICAL REVIEW That was a different molecule, in people with a specific muscle disease, with no comparison group, so it doesn’t tell you what LR3 would do.

What “receptor grade” means

“Receptor grade” is a product-grade name from lab-supply catalogs. The name points to receptor-binding experiments, the kind of test-tube work where scientists measure how a molecule attaches to its docking point on cells. It isn’t a regulatory standard, and it doesn’t certify sterility or human safety.

To be fair to the term, genuine lab-reagent listings under this name usually do come with real specifications, such as a purity figure, an endotoxin limit, and a “research use only” notice. Those specs are written for lab work, though. And the words “receptor grade” on a consumer vial don’t show that the product came from a lab supplier or meets any spec at all.

Why IGF-1 LR3 “before and after” results are unreliable

About 2,100 people a month search for IGF-1 LR3 “before and after” photos. It’s worth knowing why those results can’t tell you much, even when they’re posted in good faith.

There’s no comparison group, so there’s no way to know what would have happened with the same training and diet alone. Many people take several compounds at once, so any change can’t be credited to one of them. The poster usually can’t know what was actually in the vial (more on that below). People naturally share their best photos, and lighting, a post-workout pump, and time of day all change how a body looks.

Water matters too. Muscle stores glycogen, its supply of stored carbohydrate, along with at least 3 grams of water per gram, according to a small study in cyclists (Fernández-Elías et al., 2015). ⚠ NEEDS MEDICAL REVIEW So changes in diet can make muscles look fuller in a photo without any new muscle being built.

Is IGF-1 LR3 legal? FDA status and the sports ban

IGF-1 LR3 is not FDA-approved for any use, and it has no legal path to be made by compounding pharmacies; it’s sold as “research use only,” as of October 2026.

It isn’t listed in FDA’s records of approved drugs or licensed biological products. FDA’s substance registry does hold an ingredient ID for it, but that page states the ID “does not imply any regulatory review or approval”. It doesn’t appear on any of FDA’s compounding lists either. It’s absent from the 503A nomination categories, from the list of substances flagged for significant safety risks, and from the approved bulks list in federal rules.

Its size is the bigger obstacle. FDA defines a protein as a chain of more than 40 amino acids, and IGF-1 LR3 has 83. That makes it a biologic, meaning a large, protein-based medicine that FDA regulates under stricter rules than small-molecule drugs. FDA says biologics “are not eligible for the exemptions for compounded drugs”, and that rule took effect for proteins in March 2020. So unlike some smaller peptides, there’s no compounding route for IGF-1 LR3 to move into.

For athletes, the World Anti-Doping Agency’s 2026 Prohibited List prohibits IGF-1 and its analogues at all times, in and out of competition. IGF-1 LR3 is one of those analogues.

For how these categories work across all peptides, see how the FDA classifies peptides, how compounding differs from FDA approval, are peptides legal?, and our regulatory tracker.

Where IGF-1 LR3 is actually sold, and what that means

You won’t find IGF-1 LR3 at a regular pharmacy. It’s mostly sold by “research use only” websites directly to consumers, with no prescription and no clinician involved. That channel comes with no FDA manufacturing oversight. No regulator checks that the vial holds IGF-1 LR3 at the stated amount, that it’s sterile, or that it’s free of bacterial endotoxin (toxins that can cause fever and inflammatory reactions). ⚠ NEEDS MEDICAL REVIEW No regulator checks that the protein is correctly folded and active, and the channel doesn’t come with the legal protections of a prescription filled at a licensed pharmacy.

That gap has shown up in testing. A German anti-doping lab analyzed a black-market vial sold for injection. It found a lab-research version of the protein with a purification tag still attached, which the lab judged to be “a by-product from biochemical studies” rather than something made for injection (Kohler et al., 2010). The same lab’s review of products seized in 2009 reported “unpurified long-R3-IGF-1” (PubMed 21204286). These are findings on individual products from 2009 and 2010. They show the gap is real, but not how common bad products are today.

There is a fair point on the other side. Independent labs offer identity and purity testing specific to IGF-1 LR3, and some research-use vendors publish third-party results, which is more than many do. That testing tells you more than nothing about whether the vial holds the right molecule in roughly the right amount. The standard test, HPLC (a lab method that separates and measures what’s in a sample), doesn’t check sterility, endotoxin, or whether the protein is correctly folded and active. ⚠ NEEDS MEDICAL REVIEW Some testing services offer endotoxin testing as a paid add-on, according to one commercial testing service that sells these tests and publishes results (Finnrick). ⚠ NEEDS MEDICAL REVIEW Even a clean result covers one batch, and it doesn’t make a product verified, safe, or legal.

Compounding pharmacies have no legitimate route to it, for the biologic reasons above. One FDA inspection report from 2018 on a Kentucky compounding firm listed an IGF-1 LR3 lot among products that failed sterility testing (FDA Form 483). That was an inspection observation, not a final agency ruling. Some telehealth clinics and medspas also publish pages about IGF-1 LR3. If a clinic does provide it, a clinician is genuinely involved. But that doesn’t change the product’s status, because there’s still no approved or legally compoundable version to prescribe.

For contrast, mecasermin (Increlex) is prescription-only and filled at a licensed pharmacy. That channel gives you FDA-reviewed manufacturing, a verified dose, and specialist supervision. It isn’t a source of IGF-1 LR3, and it isn’t meant for adults or for building muscle.

Why we don’t publish IGF-1 LR3 dosing

About 2,200 people a month search for IGF-1 LR3 dosing. We don’t publish it, for two reasons.

First, we found no human dose-finding studies for IGF-1 LR3, so any dose you see online wasn’t worked out in human research. ⚠ NEEDS MEDICAL REVIEW Second, we don’t yet work with a credentialed medical reviewer. Until one signs off, we publish no dosing for any compound. You can read how that works in our editorial policy.

Key sources

1. FDA. Increlex (mecasermin) prescribing information, 2025.
2. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026).
3. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated May 14, 2026).
4. 21 CFR 600.3(h)(6), definition of “protein.”
5. FDA. Compounding and the FDA: Questions and Answers (“Can biologics be compounded?”).
6. Tomas FM et al. Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs. Growth Regul. 1993;3(1):40-4.
7. Tomas FM et al. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection.
8. Long [R3] IGF-I reduces growth, plasma GH, IGFBP-3 and endogenous IGF-I concentrations in pigs.
9. Kohler M et al. Detection of His-tagged Long-R3-IGF-I in a black market product. Growth Horm IGF Res. 2010;20(5):386-90.
10. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol. 2026;17:1822475.

FAQs about IGF-1 LR3